Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.69 |
| ▸ | TP53 | P04637 | 3/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 7/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16806096 | 0.94 | ALDH1A1 (0.62) | ALDH1A1HIF1ATP53CYP3A4MAPK1 | |
| SCHEMBL101492 | 0.93 | ALDH1A1 (0.78) | ALDH1A1HIF1ATP53CYP3A4MAPK1 | |
| SCHEMBL16805963 | 0.90 | ALDH1A1 (0.58) | ALDH1A1HIF1ATP53CYP3A4MAPK1 | |
| SCHEMBL20148970 | 0.90 | ALDH1A1 (0.62) | ALDH1A1HIF1ATP53CYP3A4MAPK1 | |
| SCHEMBL18808382 | 0.89 | ALDH1A1 (0.56) | ALDH1A1HIF1ATP53CYP3A4MAPK1 | |
| Butadiene SCHEMBL10409182 | 0.88 | ALDH1A1 (0.72) | ALDH1A1HIF1ATP53CYP3A4MAPK1 | |
| SCHEMBL19652444 | 0.86 | ALDH1A1 (0.69) | ALDH1A1HIF1ATP53CYP3A4MAPK1 | |
| SCHEMBL20690222 | 0.86 | ALDH1A1 (0.69) | ALDH1A1HIF1ATP53CYP3A4MAPK1 | |
| SCHEMBL268293 | 0.86 | ALDH1A1 (0.69) | ALDH1A1HIF1ATP53CYP3A4MAPK1 | |
| Acrylic Acid SCHEMBL9170386 | 0.86 | ALDH1A1 (0.69) | ALDH1A1HIF1ATP53CYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160282718-A1 | LITHOGRAPHIC PRINTING PLATE PRECURSOR | AGFA OFFSET BV (BE) | 2016-09-29 | — | — | US | disclosed |
| US-20160282718-A1 | LITHOGRAPHIC PRINTING PLATE PRECURSOR | AGFA OFFSET BV (BE) | 2016-09-29 | — | — | US | disclosed |
| WO-2015086659-A1 | A LITHOGRAPHIC PRINTING PLATE PRECURSOR AND MONOMER | AGFA GRAPHICS NV (BE) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160282718-A1 | LITHOGRAPHIC PRINTING PLATE PRECURSOR | LOXL1, LOXL2, LOXL3 | ALDH1A1 1892/4885HIF1A 2290/4885TP53 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.